Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

2.2K

Treatment of multiple sclerosis in children and its challenges

Sona Narula1, Brenda Banwell1

  • 1Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia, Division of Neurology, Philadelphia, PA 19104, United States.

Presse Medicale (Paris, France : 1983)
|March 7, 2015
PubMed

Insights

Pediatric multiple sclerosis (MS) requires prompt diagnosis and treatment. Children with MS often experience cognitive deficits and high relapse rates, necessitating early disease-modifying therapy.

Area of Science:

  • Neurology
  • Pediatrics
  • Immunology

Background:

  • Pediatric multiple sclerosis (MS) is a rare but significant autoimmune demyelinating disease affecting children and adolescents.
  • Early diagnosis and intervention are crucial for managing pediatric MS, which differs from adult-onset MS.

Purpose of the Study:

  • To review current understanding of pediatric multiple sclerosis (MS).
  • To discuss available and emerging treatment options for pediatric MS.
  • To highlight challenges in managing MS in young patients.

Main Methods:

  • This is a review article synthesizing existing literature on pediatric MS.
  • It examines clinical presentation, diagnostic considerations, and therapeutic strategies.
  • Focuses on disease-modifying therapies (DMTs) and management challenges.

Main Results:

  • Pediatric MS onset is associated with cognitive deficits in at least one-third of patients, with potential for cognitive decline.
  • Patients often present with high relapse rates and significant lesion burden early in the disease course.
  • Early initiation of disease-modifying therapy is recommended for pediatric MS patients.

Conclusions:

  • Prompt recognition of demyelination symptoms is vital for timely diagnosis and treatment of pediatric MS.
  • Pediatric MS requires tailored treatment approaches, considering high disease activity and cognitive impact.
  • Ongoing research into novel therapies and management strategies is essential for improving outcomes in this population.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

59.0K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
391
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
863
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
362
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
507